Physician profile
Kate E Oberlin
NPI 1871910893
$7,466.51
in general payments reported to CMS, 2019-2025
30 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $557 · 2021: $1,169 · 2022: $1,313 · 2023: $880 · 2024: $1,534 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,019 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,019.27 |
| Education | $154.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,196.43 | 2019-2025 | |
| Pfizer INC. | $817.67 | 2019-2025 | |
| Lilly USA, LLC | $744.74 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $688.90 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $669.20 | 2020-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $508.18 | 2020-2025 | Tremfya |
| Galderma Laboratories, L.P. | $491.75 | 2019-2025 | Nemluvio, Aklief |
| Incyte Corporation | $431.93 | 2021-2025 | Opzelura |
| Genzyme Corporation | $282.43 | 2020-2025 | |
| Amgen INC. | $275.76 | 2019-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.25 | 2023-2025 | Spevigo |
| Ucb, INC. | $212.21 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $196.33 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $126.33 | 2021-2025 | |
| Stemline Therapeutics INC. | $112.48 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $84.81 | 2021-2025 | Spevigo, Adbry |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Almirall LLC | $40.41 | 2019-2025 | Klisyri |
| Organon LLC | $37.43 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $37.19 | 2022-2023 | |
| Dermira, INC. | $33.19 | 2020-2021 | |
| Epi Health, LLC | $30.00 | 2022 | |
| Biofrontera INC. | $28.78 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.62 | 2022-2025 | Sotyktu |
| Celgene Corporation | $24.97 | 2019 | |
| X4 Pharmaceuticals, INC. | $19.15 | 2025 | Xolremdi |
| Journey Medical Corporation | $18.00 | 2023 | |
| Arcutis Biotherapeutics, INC. | $15.62 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.67 | 2020 | |
| Prugen, INC. Pharmaceuticals | $8.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Oberlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.